Gene Logic Inc - Amended Current report filing (8-K/A)
October 18 2007 - 4:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report: October 18, 2007
(Date of earliest event reported): October 12, 2007
Gene Logic Inc.
(Exact Name of Registrant as Specified in Charter)
Delaware 0-23317 06-1411336
(State or other (Commission File Number) (IRS Employer
jurisdiction Identification No.)
of incorporation)
|
50 West Watkins Mill Road, Gaithersburg, Maryland 20878
(Address of principal executive office) (Zip Code)
Registrant's telephone number, including area code: (301) 987-1700
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions (see General Instruction A.2. below):
[ ] Written communication pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.135-4(c))
Potential persons who are to respond to the collection of information contained
in this form are not required to respond unless the form displays a currently
valid OMB control number.
Item 5.02 Departure of Directors or Principal Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
By an Interim Report on Form 8K filed on June 22, 2007, Gene Logic announced
that, effective June 18, 2007, Dr. Louis Tartaglia resigned his position as
Chief Scientific Officer of Gene Logic Inc.
On October 12, 2007, Gene Logic received the fully signed agreement pursuant to
which Dr. Tartaglia will act as a special adviser to the Company with regard to
its Drug Repositioning business. Under the agreement, Dr. Tartaglia will receive
a retainer at a rate of $25,000 per year, plus hourly pay of $150.00 for
specific services. The agreement is for a term of twelve months beginning
September 1, 2007 and may be extended by mutual agreement.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
Exhibit Number Description
-------------- -----------
10.98 Advisory Services Agreement between Gene Logic Inc.
and Louis Tartaglia
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENE LOGIC INC.
Date: October 18, 2007 By: /s/ Philip L. Rohrer, Jr.
--------------------------
Philip L. Rohrer, Jr.
Chief Financial Officer
|
EXHIBIT INDEX
Exhibit Number Description
-------------- -----------
10.98 Advisory Services Agreement between Gene Logic Inc.
and Louis Tartaglia
|
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Jul 2024 to Aug 2024
Gene Logic Inc. (MM) (NASDAQ:GLGC)
Historical Stock Chart
From Aug 2023 to Aug 2024